Latest Commercialisation News

Omega Oil and Gas has secured a significant 19.43% equity interest in Elixir Energy, strengthening its foothold in Queensland’s Taroom Trough ahead of key drilling activities in 2026.

Elixir Energy secures $16.6 million in a capital raise led by Omega Oil and Gas, unlocking Phase-2 of its strategic plan to define reserves in Queensland’s Taroom Trough. This funding accelerates appraisal drilling and production testing, positioning Elixir for a pivotal year ahead.

Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.

Iondrive Limited has successfully raised $4 million through a share placement to accelerate the commercialisation of its innovative e-waste recycling technology in the United States.

Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.

Sea Forest Limited launches a $20.5 million IPO on the ASX to scale production and commercialisation of SeaFeed™, a scientifically validated livestock feed additive that cuts methane emissions by up to 80% while boosting productivity.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

Chariot Corporation and partners have formalized a phased small-scale mining initiative in Nigeria, aiming to unlock near-term lithium production while advancing larger exploration goals.

Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

New data reveals that Thoroughbred racehorses free from oxidative stress are significantly more likely to win or place, spotlighting OxiDx’s patented biomarker test as a game-changer in equine performance and welfare.